Released on: January 22, 2013, 11:46 am
Author: Biosortia Pharmaceuticals
Industry: Biotech, Healthcare, Chemicals, Pharmaceuticals

Biosortia Pharmaceuticals Hires Kurt Dieck as President and CEO to Accelerate Strategy to Develop and License New Highly Active Compounds from Unculturable Aquatic Microbial Consortia

Dublin, Ohio, January 22, 2013, 11:46 am – /EPR NETWORK/ — Kurt Dieck formerly SVP of Strategy and Business Execution at Cardinal Health, will lead early stage drug discovery business at Biosortia Pharmaceuticals. Dieck was named President and CEO in November 2012 and has quickly identified other key executives, including Dr. Guy Carter, former Natural Product head at Wyeth Pharmaceuticals, as his Chief Science Officer. In conjunction, other collaboration partners have joined the team, including NOAA (National Oceanic and Atmospheric Administration), NCI (National Cancer Institute) and key universities, to strategically accelerate the development of novel drug leads in the therapeutic areas of cancer, infectious diseases, inflammation and neurological disorders. Biosortia Pharmaceuticals has seen promising early results with dozens of novel compounds having already been requested, and are under evaluation with NCI and Eli Lilly.

more…